Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, Elena Galvani, Shannon Burke, Ankita Varshine, Raymond Rothstein, Kevin Schifferli, Noel R Monks, Johann Foloppe, Nathalie Silvestre, Eric Quemeneur, Christelle Demeusoit, Patricia Kleinpeter, Puja Sapra, Carl Barrett, Scott A Hammond, Elizabeth J Kelly, Jason Laliberte, Nicholas M Durham, Michael Oberst, Maria A S Broggi
Oncolytic viruses are engineered to selectively kill tumor cells and have demonstrated promising results in early-phase clinical trials. To further modulate the innate and adaptive immune system, we generated AZD4820, a vaccinia virus engineered to express interleukin-12 (IL-12), a potent cytokine involved in the activation of natural killer (NK) and T cells and the reprogramming of the tumor immune microenvironment. Testing in cultured human tumor cell lines demonstrated broad in vitro oncolytic activity and IL-12 transgene expression...
March 21, 2024: Mol Ther Oncol